(19)
(11)EP 3 690 063 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
04.11.2020 Bulletin 2020/45

(43)Date of publication A2:
05.08.2020 Bulletin 2020/32

(21)Application number: 19217908.3

(22)Date of filing:  24.11.2015
(51)International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 25.11.2014 EP 14194732

(62)Application number of the earlier application in accordance with Art. 76 EPC:
15801743.4 / 3224377

(71)Applicant: AIT Austrian Institute of Technology GmbH
1220 Wien (AT)

(72)Inventors:
  • WIELSCHER, Matthias
    1020 Wien (AT)
  • WEINHÄUSEL, Andreas
    7311 Neckenmarkt (AT)
  • VIERLINGER, Klemens
    1090 Wien (AT)
  • NOEHAMMER, Christa
    1100 Wien (AT)
  • ZIESCHE, Rolf
    7100 Neusiedl am See (AT)
  • GSUR, Andrea
    1130 Wien (AT)

(74)Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)

  


(54)DIAGNOSIS OF LUNG CANCER


(57) The present invention relates to specifically methylated nucleic acids, methods of diagnosing lung cancer or a predisposition therefor, and a corresponding kit.





Search report





















Search report